Geoff Meacham, PhD
Managing Director, Global Head of Biotech Research, Barclays
Chairman, Company Screening Committee

Geoff Meacham, serves as a Managing Director and Senior Research Analyst at Barclays PLC, Research Division. Dr. Meacham joined Barclays in December 2014 and covers the equities sector in the North America region, and the biotechnology and pharmaceutical sectors. Prior to this, he served as a Managing Director and Global Head of Biotechnology Equity Research at JP Morgan Chase & Co, Research Division. He served as Senior Analyst at JP Morgan Chase & Co, Research Division. He joined JP Morgan Chase & Co, Research Division in 2004, and catered to the biotechnology sector research in United States. Dr. Meacham was J. P. Morgan's Lead Large-Cap Biotech Analyst for 10 years. Prior to that, he was a Biotechnology Analyst at UBS Investment Bank, Research Division following early stage biotech and life science companies for about four years. His research coverage spans from large-cap biotech companies with a global reach to small, development stage companies. He has also worked in the pharmaceutical industry for two years in a research and development capacity. Prior to his career on Wall Street, he worked in industry at Solvay Pharmaceuticals. He has been a Director of Accuitis, Inc., since November 2015. He has been ranked for the past five years in the Institutional Investor poll since 2007, including a number 2 ranking since 2008. Dr. Meacham earned a Ph.D. in Molecular and Cellular Biology from UAB, and a BS in Biology and Microbiology from the University of Georgia.